Status:
COMPLETED
A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Metabolism and Nutrition Disorder
Obesity
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
This trial is conducted in Europe. The aim of this clinical trial is to investigate the effect of liraglutide on gastric emptying, energy expenditure and appetite, and to evaluate liraglutide pharmaco...
Eligibility Criteria
Inclusion
- Body Mass Index (BMI) between 30.0-40.0 kg/m2
- Stable body weight (below 5 kg body weight change during past 3 month)
- Fasting plasma glucose below 7.0 mmol/L
Exclusion
- Presence or history of cancer or any clinically significant cardiac, metabolic, renal, gastrointestinal, hepatic, endocrine, dermatological, haematological, or psychiatric diseases or disorders, considered by the Investigator to have influence of the results of this trial
- History of chronic pancreatitis or idiopathic acute pancreatitis
- Current or history of treatment with medications that may cause significant weight gain, within 12 months prior to screening
- Use of weight lowering pharmacotherapy within the last 3 months prior to trial start
- Previous or scheduled (during the trial period) surgical treatment for obesity
- Diagnosed type 1 or type 2 diabetes
- Smoking habitually as judged by the Investigator
- Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods if not sterile or post-menopausal
Key Trial Info
Start Date :
September 16 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 8 2011
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00978393
Start Date
September 16 2009
End Date
June 8 2011
Last Update
July 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Maastricht, Netherlands, 6229 ER